February 27, 2015 5:03 PM ET


Company Overview of MithraGen, Inc.

Company Overview

MithraGen, Inc. develops immunotherapies for T and B cells for the treatment and prevention of cancers and infectious diseases. It offers RetroVax, a product platform technology, which turns antigen containing class I and II epitopes into an immunostimulant. The company also provides RetroVax therapeutic vaccines. MithraGen, Inc. was formerly known as MithraTech, Inc. The company is based in Houston, Texas.

8030 El Rio

Houston, TX 77054

United States





Key Executives for MithraGen, Inc.

Chairman of the Board, Chief Executive Officer and President
Scientific Founder and Director
Chief Financial Officer and Vice President of Finance & Administration
Age: 59
Vice President of Research and Development
Compensation as of Fiscal Year 2014.

Similar Private Companies By Industry

Company Name Region
CeNeRx BioPharma, Inc. United States
Phrixus Pharmaceuticals, Inc. United States
Product Quest Manufacturing, LLC United States
McCoy Enterprises LLC United States
BioChemics, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MithraGen, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.